Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02646475 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Metabolic Effects of Angiotensin-(1-7)

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv19
  2. Enrollment target: 19 to 26
    • Study site revised
    v18
  3. Primary and study completion dates: Dec 2026 to Dec 2029v17
  4. Primary and study completion dates: Dec 2023 to Dec 2026v16
  5. Re-verified, no change to tracked fieldsv15
Show 13 earlier versionsHide 13 earlier versions
  1. Primary and study completion dates: Dec 2022 to Dec 2023v14
  2. Primary and study completion dates: Dec 2021 to Dec 2022v13
  3. Re-verified, no change to tracked fieldsv12
  4. Primary and study completion dates: Dec 2020 to Dec 2021v11
  5. Primary and study completion dates: Dec 2019 to Dec 2020v10
  6. Primary and study completion dates: Dec 2018 to Dec 2019v9
  7. Re-verified, no change to tracked fieldsv8
  8. Primary and study completion dates: Jan 2018 to Dec 2018v7
  9. Phase: Early Phase 1 to Phase 1v6
  10. 2 versions Re-verified since Jul 26, 2016, no change to tracked fieldsv4-v5
  11. Site contact updatedv3
  12. Trial status: Active, Not Recruiting to Recruiting
    • Start date: Dec 2015 to Feb 2016
    • Study sites: 0 to 1
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Vanderbilt University
47 trials monitored
See 4 trials at risk
Obesity
3,874 trials monitored
See 152 trials at risk
Hypertension
1,925 trials monitored
See 99 trials at risk
The overall purpose of this study is to learn more about the metabolic effects of angiotensin-(1-7) in the insulin resistant state associated with obesity. Pharmacologic approaches to increase angiotensin-(1-7) levels or its actions are currently in development for treatment of metabolic-related diseases such as obesity and type II diabetes, based on findings from animal studies. It is unclear if this peptide contributes to the regulation of metabolism in humans. The investigators will test if angiotensin-(1-7) infusion can improve insulin sensitivity measured by hyperinsulinemic-euglycemic clamp methods in individuals with obesity and insulin resistance. The investigators will also examine for changes in blood pressure and related hemodynamic and hormonal changes following angiotensin-(1-7) infusion.
Trial Details
NCT Number NCT02646475
Lead Sponsor Vanderbilt University
Conditions
(from sponsor)		 Obesity, Insulin Resistance, Hypertension, Metabolic Cardiovascular Syndrome
Related terms Hypertension, Insulin Resistance, Metabolic Syndrome, Obesity
Enrollment 26 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov